NICE issues final draft guidance for nirmatrelvir plus ritonavir for treating COVID-19 (partial review of TA878)
Final draft recommendations published on the use of nirmatrelvir plus ritonavir for COVID-19
Final draft guidance for nirmatrelvir plus ritonavir has been published by the National Institute for Health and Care Excellence (NICE), following a partial review of Multiple Technology Appraisal (MTA) TA878.
The final draft guidance recommends nirmatrelvir plus ritonavir as an option for treating COVID-19 in adults for some additional risk groups, namely:
- age 70 years and over
- body mass index (BMI) of 35 kg/m2 or more
- heart failure
The Scottish Medicines Consortium (SMC) has had direct input into the decision-making committee that produced the final draft guidance.
Any amendments to the SMC collaborative advice document will occur following publication of NICE final guidance.
You can read more about the final draft guidance recommendations here: Final draft guidance | Project documents | Nirmatrelvir plus ritonavir for treating COVID-19 (Partial Rapid Review of TA878) [ID6262] | Guidance | NICE